Insulin aspart/insulin protomine aspart biosimilar - GEROPHARM
Alternative Names: GP-40081; Insulin aspart biphasic biosimilar - GEROPHARM; Insulin-protomine-aspart/insulin-aspart -GEROPHARMLatest Information Update: 28 Jan 2022
Price :
$50 *
At a glance
- Originator GEROPHARM
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Type 2 diabetes mellitus
Most Recent Events
- 01 Jan 2022 Preregistration for Type 2 diabetes mellitus in Russia (SC) before January 2022 (GEROPHARM pipeline, January 2022)
- 20 Jan 2020 Phase-III clinical trials in Type 2 diabetes mellitus in Russia (SC) (NCT04226105)
- 13 Jan 2020 Geopharm plans a phase-III trial for Type-2 diabetes mellitus (In adults, In the elderly) in Russia (SC, Injection), (NCT04226105)